Tempest Therapeutics (NASDAQ:TPST) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Tempest Therapeutics (NASDAQ:TPST) issued its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04), FiscalAI reports.

Tempest Therapeutics Trading Down 3.3%

Shares of NASDAQ TPST traded down $0.04 during midday trading on Thursday, reaching $1.17. The company’s stock had a trading volume of 285,197 shares, compared to its average volume of 182,467. The stock has a 50 day simple moving average of $1.07 and a 200-day simple moving average of $1.72. The stock has a market capitalization of $18.70 million, a price-to-earnings ratio of -0.19 and a beta of -1.72. Tempest Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $12.23.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Zacks Research lowered shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tempest Therapeutics in a report on Monday, July 13th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tempest Therapeutics stock. Vanguard Group Inc. increased its stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 162,560 shares of the company’s stock after acquiring an additional 27,952 shares during the period. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 as of its most recent filing with the SEC. 22.52% of the stock is owned by hedge funds and other institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.